{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:46:32Z","timestamp":1782974792130,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:00:00Z","timestamp":1454544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s10384-016-0426-4","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T09:57:26Z","timestamp":1454579846000},"page":"72-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Association between glaucoma eye drops and hyperemia"],"prefix":"10.1007","volume":"60","author":[{"given":"Masahide","family":"Yanagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Hoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"426_CR1","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/archopht.119.12.1819","volume":"119","author":"HA Quigley","year":"2001","unstructured":"Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: proyecto VER. Arch Ophthalmol. 2001;119:1819\u201326.","journal-title":"Arch Ophthalmol"},{"key":"426_CR2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0161-6420(95)31055-X","volume":"102","author":"JM Tielsch","year":"1995","unstructured":"Tielsch JM, Katz J, Quigley HA, Javitt JC, Sommer A. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology. 1995;102:48\u201353.","journal-title":"Ophthalmology"},{"key":"426_CR3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/bjo.2007.135111","volume":"93","author":"F Honrubia","year":"2009","unstructured":"Honrubia F, Garcia-Sanchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009;93:316\u201321.","journal-title":"Br J Ophthalmol"},{"key":"426_CR4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.ophtha.2007.11.023","volume":"115","author":"DS Friedman","year":"2008","unstructured":"Friedman DS, Hahn SR, Gelb L, Tan J, Shah SN, Kim EE, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the glaucoma adherence and persistency study. Ophthalmology. 2008;115:1320\u20137.","journal-title":"Ophthalmology"},{"key":"426_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10384-012-0188-6","volume":"57","author":"MH Park","year":"2013","unstructured":"Park MH, Kang KD, Moon J. Noncompliance with glaucoma medication in Korean patients: a multicenter qualitative study. Jpn J Ophthalmol. 2013;57:47\u201356.","journal-title":"Jpn J Ophthalmol"},{"key":"426_CR6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","volume":"16","author":"RA Lewis","year":"2007","unstructured":"Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98\u2013103.","journal-title":"J Glaucoma"},{"key":"426_CR7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ophtha.2006.07.064","volume":"114","author":"AG Konstas","year":"2007","unstructured":"Konstas AG, Kozobolis VP, Katsimpris IE, Boboridis K, Koukoula S, Jenkins JN, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114:653\u20137.","journal-title":"Ophthalmology"},{"key":"426_CR8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1185\/030079906X120959","volume":"22","author":"J Garcia-Feijoo","year":"2006","unstructured":"Garcia-Feijoo J, Martinez-de-la-Casa JM, Castillo A, Mendez C, Fernandez-Vidal A, Garcia-Sanchez J. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. Curr Med Res Opin. 2006;22:1689\u201397.","journal-title":"Curr Med Res Opin"},{"key":"426_CR9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/jop.2006.22.449","volume":"22","author":"MJ Chen","year":"2006","unstructured":"Chen MJ, Chen YC, Chou CK, Hsu WM. Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. J Ocul Pharmacol Ther. 2006;22:449\u201354.","journal-title":"J Ocul Pharmacol Ther"},{"key":"426_CR10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/112067210601600113","volume":"16","author":"S Parmaksiz","year":"2006","unstructured":"Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73\u201380.","journal-title":"Eur J Ophthalmol"},{"key":"426_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10384-011-0107-2","volume":"56","author":"T Yoneda","year":"2012","unstructured":"Yoneda T, Sumi T, Takahashi A, Hoshikawa Y, Kobayashi M, Fukushima A. Automated hyperemia analysis software: reliability and reproducibility in healthy subjects. Jpn J Ophthalmol. 2012;56:1\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"426_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IJG.0b013e3181d26024","volume":"20","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi H, Kobayashi K. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect. J Glaucoma. 2011;20:3\u20136.","journal-title":"J Glaucoma"},{"key":"426_CR13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archopht.123.2.186","volume":"123","author":"ES Arcieri","year":"2005","unstructured":"Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186\u201392.","journal-title":"Arch Ophthalmol"},{"key":"426_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF02853166","volume":"18","author":"R Noecker","year":"2001","unstructured":"Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205\u201315.","journal-title":"Adv Ther."},{"key":"426_CR15","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1167\/iovs.04-1331","volume":"46","author":"JM Guenoun","year":"2005","unstructured":"Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444\u201350.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"426_CR16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","volume":"27","author":"MY Kahook","year":"2008","unstructured":"Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339\u201343.","journal-title":"Cornea"},{"key":"426_CR17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/jop.1999.15.323","volume":"15","author":"TL Davis","year":"1999","unstructured":"Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocul Pharmacol Ther. 1999;15:323\u201336.","journal-title":"J Ocul Pharmacol Ther"},{"key":"426_CR18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/108076801753266802","volume":"17","author":"MR Hellberg","year":"2001","unstructured":"Hellberg MR, Sallee VL, McLaughlin MA, Sharif NA, Desantis L, Dean TR, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421\u201332.","journal-title":"J Ocul Pharmacol Ther"},{"key":"426_CR19","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.04-1527","volume":"46","author":"T Ota","year":"2005","unstructured":"Ota T, Murata H, Sugimoto E, Aihara M, Araie M. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci. 2005;46:2006\u201311.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"426_CR20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.me.35.020184.001211","volume":"35","author":"LL Remis","year":"1984","unstructured":"Remis LL, Epstein DL. Treatment of glaucoma. Annu Rev Med. 1984;35:195\u2013205.","journal-title":"Annu Rev Med"},{"key":"426_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/108076803762718088","volume":"19","author":"RM Feldman","year":"2003","unstructured":"Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:23\u201335.","journal-title":"J Ocul Pharmacol Ther"},{"key":"426_CR22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","volume":"103","author":"CB Camras","year":"1996","unstructured":"Camras CB, The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology. 1996;103:138\u201347.","journal-title":"Ophthalmology"},{"key":"426_CR23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archopht.1996.01100140137004","volume":"114","author":"HK Mishima","year":"1996","unstructured":"Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension; a 12-week study. Arch Ophthalmol. 1996;114:929\u201332.","journal-title":"Arch Ophthalmol"},{"key":"426_CR24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/BF02169445","volume":"227","author":"XD Martin","year":"1989","unstructured":"Martin XD, Rabineau PA. Vasoconstrictive effect of topical timolol on human retinal arteries. Graefes Arch Clin Exp Ophthalmol. 1989;227:526\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"426_CR25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14656566.2012.662219","volume":"13","author":"M Digiuni","year":"2012","unstructured":"Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012;13:723\u201345.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-016-0426-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-016-0426-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-016-0426-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T07:58:43Z","timestamp":1567583923000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-016-0426-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1007\/s10384-016-0426-4","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}